Business Wire

Wikifarmer Raises Large Seed Round From World Class Investors to Spread Sustainable Agricultural Knowledge Across the Globe and Digitize Agricultural B2B Commerce

Share

Wikifarmer, a global platform with the mission of empowering farmers through educating them and offering them access to the open market to sell their products at fair prices and mentioned as the “Wikipedia of Farming” by the FAO of the UN, has successfully completed a Seed financing round with the support of a group of world class investors such as Mathias Kamprad, Inter IKEA BoD, Patrick and Cynthia Odier of the Lombard Odier Private Bank, Sophia Bendz, venture capitalist and former Spotify global director of marketing, Alexandre Vilgrain, C.E.O. of SOMDIAA group, the Constantakopoulos foundation and with the participation of Metavallon Venture Capital, a leading Greek VC firm.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005694/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Wikifarmer's co-founders, Petros Sagos (left) and Ilias Sousis (Photo: Business Wire)

Agriculture is still one of the least digitized industries in the world and this has not allowed the industry’s value chain to be disrupted, but instead has created a paradox; farmers are the most valuable part of agriculture’s value chain but make the least profit out of it. In addition to that, most farmers are still using the techniques of their ancestors to grow their crops. The need for up-to-date sustainable agriculture knowledge has never been greater in the world than today. Agriculture & food trade market is expected to exceed 6 trillion EUR in value by the end of 2025.

Wikifarmer’s platform allows farmers to access free up to date knowledge on agricultural best practices and gives them the opportunity to sell their products directly to businesses, helping them minimize or surpass the large number of intermediaries that currently exist. Wikifarmer is aiming to become the universal source for farmers searching for information and the go-to destination for people seeking to purchase agricultural products globally.

Co-founders Ilias Sousis, Peter Sagos and Harry Parianos were inspired by the negative impact that outdated practices in agriculture have on the environment, global hunger and the financial sustainability of farmers. At the same time, helping farmers make a higher profit margin out of their commercial activities will have a wider impact on the economy and on the quality of products produced.

Sousis has been a part of the management team of Google Greece for years, leading the commercial launch of YouTube in Greece and Cyprus and has had prior entrepreneurial experience in traditional commerce, while Sagos is a passionate agronomist with deep knowledge in agricultural production and a business background as he was running a seeds trading family business. Parianos is the owner and CEO of McCann Athens and has spent more than 30 years as a senior leader in the advertising industry.

Wikifarmer’s library and marketplace has already been visited by 12 million visitors from more than 200 countries while 30,000 products have been uploaded by farmers. More than 5,000 buyers - including food processing units (FMCGs, Food services, etc), Wholesalers/ Importers, Retail Stores and Hotels/Restaurants - have purchased a product directly from a farm.

The investment will be used to expand the educational content to 20 languages and to enhance Wikifarmer’s marketplace presence in Greece, Italy, France and Spain, with the objective to create a Mediterranean hub of farmers that will attract buyers from all over the world, establishing the platform in a leading place globally.

Sagos said: “We want to democratize agriculture, give farmers around the world the chance to learn new things and thus the opportunity to grow their capabilities, their crops, their earnings. This is the only way forward to make this sector more sustainable and feed the growing world population.”

Ilias Sousis, mentioned regarding the raise: “I am thrilled that a group of very important and sustainability-conscious world-class investors are sharing our vision and efforts to solve some of the biggest pain points that have troubled the sector of agriculture for hundreds of years now.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For any press or business inquiries please contact:
Mr Ilias Sousis
commercial@wikifarmer.com
+30 6936113480

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye